Canada markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.2900+0.0100 (+0.23%)
At close: 01:00PM EST
4.1400 -0.15 (-3.50%)
After hours: 03:07PM EST
Full screen
Loading interactive chart...
  • Simply Wall St.

    Longeveron Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

    Longeveron ( NASDAQ:LGVN ) Third Quarter 2022 Results Key Financial Results Net loss: US$5.24m (loss widened by 8.0...

  • GlobeNewswire

    Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

    -- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for

  • GlobeNewswire

    Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease

    MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the completion of enrollment in its Phase 2a trial of Lomecel-BTM in patients with mild Alzheimer’s Disease (AD). “We are pleased to have completed enrollment in our Phase 2a study of Lomecel-BTM for Alzheimer’s Disease. We look forward to building on our Phase 1b study, which met its